Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sinovac Biotech Ltd (NASDAQ:SVA)

5.58
Delayed Data
As of Aug 28
 +0.15 / +2.76%
Today’s Change
4.51
Today|||52-Week Range
6.00
+6.69%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$311.4M

Company Description

Sinovac Biotech Ltd. is biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal rabies vaccine. Its products include Healive, Bilive, Anflu, Panflu and PANFLU.1. The company was founded in 1993 and is headquartered in Beijing, China.

Contact Information

Sinovac Biotech Ltd.
No. 39 Shangdi Xi Road
Beijing Beijing 100085
P:861082890088
Investor Relations:
8610827998719659

Employees

Shareholders

Mutual fund holders6.22%
Other institutional19.23%
Individual stakeholders--

Top Executives

Wei Dong YinChairman, President, CEO & Secretary
Nan WangChief Financial Officer
Ming XiaVice President-Sales & Marketing
Xue Feng WangHead-International Sales
Helen G. YangHead-Investor Relations